HR. 8205Introduced
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Plain-English overview
What this bill does
Reauthorizes through FY2031 and revises federal ALS and neurodegenerative disease therapy programs, including grant oversight and FDA planning for investigational drug development and access
Key points
- Require adverse event reporting
- Direct FDA five year plan
- Modify grant safety reviews
- Extend ALS research grants
Current status
Where it stands
Status
Introduced
Latest action
2026-07-23 — Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.
Related context
Topics and policy areas
Select a topic to continue exploring related legislation, members, and committees.
Discovery signals
About these signals
Impact and Momentum are relative discovery aids calculated by Legislation Lemur. They help you scan the congressional record; they are not predictions, endorsements, ideological ratings, or measures of policy importance.
Impact ScoreOverall observed legislative footprint and accumulated activity.
MomentumHow recently active or changing the bill appears in available data.